Mitochondria-mediated damage to dopaminergic neurons in Parkinson's disease (Review)

Liu,Xiao‑Liang; Wang,Ying‑Di; Yu,Xiu‑Ming; Li,Da‑Wei; Li,Guang‑Ren

doi:10.3892/ijmm.2017.3255

Mitochondria-mediated damage to dopaminergic neurons in Parkinson's disease (Review)

Authors:
- Xiao‑Liang Liu
- Ying‑Di Wang
- Xiu‑Ming Yu
- Da‑Wei Li
- Guang‑Ren Li
View Affiliations

Affiliations: Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 132021, P.R. China, Department of Urinary Surgery, The Tumor Hospital of Jilin Province, Changchun, Jilin 130012, P.R. China, Department of Immunology, The First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin 130021, P.R. China, Department of Neurology, Affiliated Hospital of Beihua University, Jilin, Jilin 132000, P.R. China, Department of Neurology, The Third Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: November 16, 2017 https://doi.org/10.3892/ijmm.2017.3255
Pages: 615-623

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondria are important organelles in virtually all eukaryotic cells, and are involved in a wide range of physiological and pathophysiological processes. Besides the generation of cellular energy in the form of adenosine triphosphate, mitochondria are also involved in calcium homeostasis, reactive oxygen species production and the activation of the intrinsic cell death pathway, thus determining cell survival and death. Mitochondrial abnormalities have been implicated in a wide range of disorders, including neurodegenerative disease such as Parkinson's disease (PD), and considered as a primary cause and central event responsible for the progressive loss of dopaminergic neurons in PD. Thus, reversion or attenuation of mitochondrial dysfunction should alleviate the severity or progression of the disease. The present review systematically summarizes the possible mechanisms associated with mitochondria‑mediated dopaminergic neuron damage in PD, in an attempt to elucidate the requirement for further studies for the development of effective PD treatments.

View Figures

View References

1	Forno LS: Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 55:259–272. 1996. View Article : Google Scholar : PubMed/NCBI
2	Martin LJ: Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci. 107:355–415. 2012. View Article : Google Scholar : PubMed/NCBI
3	Trancikova A, Tsika E and Moore DJ: Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal. 16:896–919. 2012. View Article : Google Scholar :
4	Ryan BJ, Hoek S, Fon EA and Wade-Martins R: Mitochondrial dysfunction and mitophagy in Parkinson's: From familial to sporadic disease. Trends Biochem Sci. 40:200–210. 2015. View Article : Google Scholar : PubMed/NCBI
5	Moon HE and Paek SH: Mitochondrial dysfunction in Parkinson's disease. Exp Neurobiol. 24:103–116. 2015. View Article : Google Scholar : PubMed/NCBI
6	Exner N, Lutz AK, Haass C and Winklhofer KF: Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. EMBO J. 31:3038–3062. 2012. View Article : Google Scholar : PubMed/NCBI
7	Mounsey RB and Teismann P: Mitochondrial dysfunction in Parkinson's disease: Pathogenesis and neuroprotection. Parkinsons Dis. 2010:6174722011.
8	Martin LJ: Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals (Basel). 3:839–915. 2010. View Article : Google Scholar
9	Reddy PH and Reddy TP: Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res. 8:393–409. 2011. View Article : Google Scholar : PubMed/NCBI
10	Reddy PH and Beal MF: Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev. 49:618–632. 2005. View Article : Google Scholar : PubMed/NCBI
11	Rostovtseva TK, Tan W and Colombini M: On the role of VDAC in apoptosis: fact and fiction. J Bioenerg Biomembr. 37:129–142. 2005. View Article : Google Scholar : PubMed/NCBI
12	Okada SF, O'Neal WK, Huang P, Nicholas RA, Ostrowski LE, Craigen WJ, Lazarowski ER and Boucher RC: Voltage-dependent anion channel-1 (VDAC-1) contributes to ATP release and cell volume regulation in murine cells. J Gen Physiol. 124:513–526. 2004. View Article : Google Scholar : PubMed/NCBI
13	Camara AK, Lesnefsky EJ and Stowe DF: Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal. 13:279–347. 2010. View Article : Google Scholar :
14	Bernardi P: Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol Rev. 79:1127–1155. 1999. View Article : Google Scholar : PubMed/NCBI
15	Teshima Y, Akao M, Jones SP and Marbán E: Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. Circ Res. 93:192–200. 2003. View Article : Google Scholar : PubMed/NCBI
16	O'Rourke B: Mitochondrial ion channels. Annu Rev Physiol. 69:19–49. 2007. View Article : Google Scholar
17	Wingrove DE and Gunter TE: Kinetics of mitochondrial calcium transport. II A kinetic description of the sodium-dependent calcium efflux mechanism of liver mitochondria and inhibition by ruthenium red and by tetraphenylphosphonium. J Biol Chem. 261:15166–15171. 1986.PubMed/NCBI
18	Bernardi P, Krauskopf A, Basso E, Petronilli V, Blachly-Dyson E, Di Lisa F and Forte MA: The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 273:2077–2099. 2006. View Article : Google Scholar : PubMed/NCBI
19	Leung AW and Halestrap AP: Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta. 1777:946–952. 2008. View Article : Google Scholar : PubMed/NCBI
20	Vyssokikh MY, Katz A, Rueck A, Wuensch C, Dörner A, Zorov DB and Brdiczka D: Adenine nucleotide translocator isoforms 1 and 2 are differently distributed in the mitochondrial inner membrane and have distinct affinities to cyclophilin D. Biochem J. 358:349–358. 2001. View Article : Google Scholar : PubMed/NCBI
21	Halestrap AP and Brenner C: The adenine nucleotide translocase: A central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem. 10:1507–1525. 2003. View Article : Google Scholar : PubMed/NCBI
22	Ojala D, Montoya J and Attardi G: tRNA punctuation model of RNA processing in human mitochondria. Nature. 290:470–474. 1981. View Article : Google Scholar : PubMed/NCBI
23	Reddy PH: Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease. J Neurochem. 96:1–13. 2006. View Article : Google Scholar
24	Brookes PS, Levonen AL, Shiva S, Sarti P and Darley-Usmar VM: Mitochondria: Regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med. 33:755–764. 2002. View Article : Google Scholar : PubMed/NCBI
25	Dröge W: Free radicals in the physiological control of cell function. Physiol Rev. 82:47–95. 2002. View Article : Google Scholar : PubMed/NCBI
26	Kudin AP, Bimpong-Buta NY, Vielhaber S, Elger CE and Kunz WS: Characterization of superoxide-producing sites in isolated brain mitochondria. J Biol Chem. 279:4127–4135. 2004. View Article : Google Scholar
27	Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL and Parker N: Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med. 37:755–767. 2004. View Article : Google Scholar : PubMed/NCBI
28	Andreyev AY, Kushnareva YE and Starkov AA: Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc). 70:200–214. 2005. View Article : Google Scholar
29	Cadenas E and Davies KJ: Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 29:222–230. 2000. View Article : Google Scholar : PubMed/NCBI
30	Kudin AP, Debska-Vielhaber G and Kunz WS: Characterization of superoxide production sites in isolated rat brain and skeletal muscle mitochondria. Biomed Pharmacother. 59:163–168. 2005. View Article : Google Scholar : PubMed/NCBI
31	Kussmaul L and Hirst J: The mechanism of superoxide production by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci USA. 103:7607–7612. 2006. View Article : Google Scholar : PubMed/NCBI
32	Rush JD and Koppenol WH: Oxidizing intermediates in the reaction of ferrous EDTA with hydrogen peroxide. Reactions with organic molecules and ferrocytochrome c. J Biol Chem. 261:6730–6733. 1986.PubMed/NCBI
33	Antunes F, Han D and Cadenas E: Relative contributions of heart mitochondria glutathione peroxidase and catalase to H(2)O(2) detoxification in in vivo conditions. Free Radic Biol Med. 33:1260–1267. 2002. View Article : Google Scholar : PubMed/NCBI
34	Morán M, Moreno-Lastres D, Marín-Buera L, Arenas J, Martín MA and Ugalde C: Mitochondrial respiratory chain dysfunction: Implications in neurodegeneration. Free Radic Biol Med. 53:595–609. 2012. View Article : Google Scholar : PubMed/NCBI
35	Gutteridge JM: Superoxide-dependent formation of hydroxyl radicals from ferric-complexes and hydrogen peroxide: An evaluation of fourteen iron chelators. Free Radic Res Commun. 9:119–125. 1990. View Article : Google Scholar : PubMed/NCBI
36	Hwang O: Role of oxidative stress in Parkinson's disease. Exp Neurobiol. 22:11–17. 2013. View Article : Google Scholar : PubMed/NCBI
37	Dias V, Junn E and Mouradian MM: The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 3:461–491. 2013.PubMed/NCBI
38	Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol. 53(Suppl 3): S26–S38. 2003. View Article : Google Scholar : PubMed/NCBI
39	Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P and Halliwell B: Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem. 69:1196–1203. 1997. View Article : Google Scholar : PubMed/NCBI
40	Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER and Mizuno Y: Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA. 93:2696–2701. 1996. View Article : Google Scholar : PubMed/NCBI
41	Li DW, Yao M, Dong YH, Tang MN, Chen W, Li GR and Sun BQ: Guanosine exerts neuroprotective effects by reversing mitochondrial dysfunction in a cellular model of Parkinson's disease. Int J Mol Med. 34:1358–1364. 2014. View Article : Google Scholar : PubMed/NCBI
42	Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, Looi WF, Huang SH, Wang H and Chan YH: Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med. 48:560–566. 2010. View Article : Google Scholar
43	Callio J, Oury TD and Chu CT: Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. J Biol Chem. 280:18536–18542. 2005. View Article : Google Scholar : PubMed/NCBI
44	Vila M and Przedborski S: Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci. 4:365–375. 2003. View Article : Google Scholar : PubMed/NCBI
45	Perier C, Bové J, Vila M and Przedborski S: The rotenone model of Parkinson's disease. Trends Neurosci. 26:345–346. 2003. View Article : Google Scholar : PubMed/NCBI
46	Sun SY, An CN and Pu XP: DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats. Brain Res Bull. 88:609–616. 2012. View Article : Google Scholar : PubMed/NCBI
47	Heikkila RE, Hess A and Duvoisin RC: Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1451–1453. 1984. View Article : Google Scholar : PubMed/NCBI
48	Barzilai A and Yamamoto K: DNA damage responses to oxidative stress. DNA Repair (Amst). 3:1109–1115. 2004. View Article : Google Scholar
49	Ruipérez V, Darios F and Davletov B: Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res. 49:420–428. 2010. View Article : Google Scholar : PubMed/NCBI
50	Mariani E, Polidori MC, Cherubini A and Mecocci P: Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J Chromatogr B Analyt Technol Biomed Life Sci. 827:65–75. 2005. View Article : Google Scholar : PubMed/NCBI
51	Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ II and Morrow JD: Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med. 33:620–626. 2002. View Article : Google Scholar : PubMed/NCBI
52	Liu W, Kato M, Akhand AA, Hayakawa A, Suzuki H, Miyata T, Kurokawa K, Hotta Y, Ishikawa N and Nakashima I: 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci. 113:635–641. 2000.PubMed/NCBI
53	Schmidt H, Grune T, Müller R, Siems WG and Wauer RR: Increased levels of lipid peroxidation products malondialdehyde and 4-hydroxynonenal after perinatal hypoxia. Pediatr Res. 40:15–20. 1996. View Article : Google Scholar : PubMed/NCBI
54	Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ II, Morrow JD and Montine TJ: Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids. 128:117–124. 2004. View Article : Google Scholar : PubMed/NCBI
55	Lotharius J and Brundin P: Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci. 3:932–942. 2002. View Article : Google Scholar : PubMed/NCBI
56	Fornstedt B and Carlsson A: A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J Neural Transm. 76:155–161. 1989. View Article : Google Scholar : PubMed/NCBI
57	Youdim MB, Edmondson D and Tipton KF: The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 7:295–309. 2006. View Article : Google Scholar : PubMed/NCBI
58	Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C and MacGregor R: Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 18:431–435. 1997. View Article : Google Scholar : PubMed/NCBI
59	Nagatsu T and Sawada M: Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: Possible implications of glial cells. J Neural Transm Suppl. 71:53–65. 2006. View Article : Google Scholar
60	Kumar MJ and Andersen JK: Perspectives on MAO-B in aging and neurological disease: Where do we go from here? Mol Neurobiol. 30:77–89. 2004. View Article : Google Scholar : PubMed/NCBI
61	Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H and Lee VM: Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem. 280:21212–21219. 2005. View Article : Google Scholar : PubMed/NCBI
62	Zecca L, Wilms H, Geick S, Claasen JH, Brandenburg LO, Holzknecht C, Panizza ML, Zucca FA, Deuschl G, Sievers J, et al: Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: Implications for Parkinson's disease. Acta Neuropathol. 116:47–55. 2008. View Article : Google Scholar : PubMed/NCBI
63	Jomova K and Valko M: Advances in metal-induced oxidative stress and human disease. Toxicology. 283:65–87. 2011. View Article : Google Scholar : PubMed/NCBI
64	Núñez MT, Urrutia P, Mena N, Aguirre P, Tapia V and Salazar J: Iron toxicity in neurodegeneration. Biometals. 25:761–776. 2012. View Article : Google Scholar : PubMed/NCBI
65	Sadrzadeh SM and Saffari Y: Iron and brain disorders. Am J Clin Pathol. 121(Suppl): S64–S70. 2004.PubMed/NCBI
66	Sian-Hülsmann J, Mandel S, Youdim MB and Riederer P: The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem. 118:939–957. 2011. View Article : Google Scholar
67	Sziráki I, Mohanakumar KP, Rauhala P, Kim HG, Yeh KJ and Chiueh CC: Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience. 85:1101–1111. 1998. View Article : Google Scholar : PubMed/NCBI
68	Lan J and Jiang DH: Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm Vienna. 104:469–481. 1997. View Article : Google Scholar : PubMed/NCBI
69	Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y and Hirsch EC: Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem. 86:1142–1148. 2003. View Article : Google Scholar : PubMed/NCBI
70	Yokoyama H, Kuroiwa H, Yano R and Araki T: Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci. 29:293–301. 2008. View Article : Google Scholar : PubMed/NCBI
71	Duchen MR: Mitochondria in health and disease: Perspectives on a new mitochondrial biology. Mol Aspects Med. 25:365–451. 2004. View Article : Google Scholar : PubMed/NCBI
72	Henchcliffe C and Beal MF: Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 4:600–609. 2008. View Article : Google Scholar : PubMed/NCBI
73	Mythri RB, Jagatha B, Pradhan N, Andersen J and Bharath MM: Mitochondrial complex I inhibition in Parkinson's disease: How can curcumin protect mitochondria? Antioxid Redox Signal. 9:399–408. 2007. View Article : Google Scholar
74	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
75	Crompton M: The mitochondrial permeability transition pore and its role in cell death. Biochem J. 341:233–249. 1999. View Article : Google Scholar : PubMed/NCBI
76	Burchell VS, Gandhi S, Deas E, Wood NW, Abramov AY and Plun-Favreau H: Targeting mitochondrial dysfunction in neurodegenerative disease: Part I. Expert Opin Ther Targets. 14:369–385. 2010. View Article : Google Scholar : PubMed/NCBI
77	Moon Y, Lee KH, Park JH, Geum D and Kim K: Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: Protective effect of coenzyme Q10. J Neurochem. 93:1199–1208. 2005. View Article : Google Scholar : PubMed/NCBI
78	McCarthy S, Somayajulu M, Sikorska M, Borowy-Borowski H and Pandey S: Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicol Appl Pharmacol. 201:21–31. 2004. View Article : Google Scholar : PubMed/NCBI
79	Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ and Beal MF: Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem. 104:1613–1621. 2008. View Article : Google Scholar
80	Dubois C, Prevarskaya N and Vanden Abeele F: The calcium-signaling toolkit: Updates needed. Biochim Biophys Acta. 1863:1337–1343. 2016. View Article : Google Scholar
81	Santo-Domingo J, Wiederkehr A and De Marchi U: Modulation of the matrix redox signaling by mitochondrial Ca(2). World J Biol Chem. 6:310–323. 2015. View Article : Google Scholar : PubMed/NCBI
82	Nicholls DG: Mitochondrial function and dysfunction in the cell: Its relevance to aging and aging-related disease. Int J Biochem Cell Biol. 34:1372–1381. 2002. View Article : Google Scholar : PubMed/NCBI
83	Kirichok Y, Krapivinsky G and Clapham DE: The mitochondrial calcium uniporter is a highly selective ion channel. Nature. 427:360–364. 2004. View Article : Google Scholar : PubMed/NCBI
84	Gincel D, Zaid H and Shoshan-Barmatz V: Calcium binding and translocation by the voltage-dependent anion channel: A possible regulatory mechanism in mitochondrial function. Biochem J. 358:147–155. 2001. View Article : Google Scholar : PubMed/NCBI
85	Takeuchi A, Kim B and Matsuoka S: The destiny of Ca(2+) released by mitochondria. J Physiol Sci. 65:11–24. 2015. View Article : Google Scholar
86	Plovanich M, Bogorad RL, Sancak Y, Kamer KJ, Strittmatter L, Li AA, Girgis HS, Kuchimanchi S, De Groot J, Speciner L, et al: MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling. PLoS One. 8:e557852013. View Article : Google Scholar : PubMed/NCBI
87	Perocchi F, Gohil VM, Girgis HS, Bao XR, McCombs JE, Palmer AE and Mootha VK: MICU1 encodes a mitochondrial EF hand protein required for Ca(2+) uptake. Nature. 467:291–296. 2010. View Article : Google Scholar : PubMed/NCBI
88	McCormack JG and Denton RM: Mitochondrial Ca²⁺ transport and the role of intramitochondrial Ca²⁺ in the regulation of energy metabolism. Dev Neurosci. 15:165–173. 1993. View Article : Google Scholar
89	Balaban RS: Cardiac energy metabolism homeostasis: Role of cytosolic calcium. J Mol Cell Cardiol. 34:1259–1271. 2002. View Article : Google Scholar : PubMed/NCBI
90	Alderton WK, Cooper CE and Knowles RG: Nitric oxide synthases: Structure, function and inhibition. Biochem J. 357:593–615. 2001. View Article : Google Scholar : PubMed/NCBI
91	Jekabsone A, Ivanoviene L, Brown GC and Borutaite V: Nitric oxide and calcium together inactivate mitochondrial complex I and induce cytochrome c release. J Mol Cell Cardiol. 35:803–809. 2003. View Article : Google Scholar : PubMed/NCBI
92	Brookes PS, Yoon Y, Robotham JL, Anders MW and Sheu SS: Calcium, ATP, and ROS: A mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 287:C817–C833. 2004. View Article : Google Scholar : PubMed/NCBI
93	Muravchick S and Levy RJ: Clinical implications of mitochondrial dysfunction. Anesthesiology. 105:819–837. 2006. View Article : Google Scholar : PubMed/NCBI
94	O'Rourke B: Pathophysiological and protective roles of mitochondrial ion channels. J Physiol. 529:23–36. 2000. View Article : Google Scholar : PubMed/NCBI
95	Di Lisa F and Bernardi P: A CaPful of mechanisms regulating the mitochondrial permeability transition. J Mol Cell Cardiol. 46:775–780. 2009. View Article : Google Scholar : PubMed/NCBI
96	Jones SP, Teshima Y, Akao M and Marbán E: Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 93:697–699. 2003. View Article : Google Scholar : PubMed/NCBI
97	Celardo I, Martins LM and Gandhi S: Unravelling mitochondrial pathways to Parkinson's disease. Br J Pharmacol. 171:1943–1957. 2014. View Article : Google Scholar :
98	Surmeier DJ, Guzman JN, Sanchez-Padilla J and Goldberg JA: The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal. 14:1289–1301. 2011. View Article : Google Scholar :
99	Perier C, Tieu K, Guégan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S and Vila M: Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA. 102:19126–19131. 2005. View Article : Google Scholar : PubMed/NCBI
100	Boatright KM and Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol. 15:725–731. 2003. View Article : Google Scholar : PubMed/NCBI
101	Kumar S: Caspase function in programmed cell death. Cell Death Differ. 14:32–43. 2007. View Article : Google Scholar
102	Javadov S, Choi A, Rajapurohitam V, Zeidan A, Basnakian AG and Karmazyn M: NHE-1 inhibition-induced cardioprotection against ischaemia/reperfusion is associated with attenuation of the mitochondrial permeability transition. Cardiovasc Res. 77:416–424. 2008. View Article : Google Scholar
103	Wallace DC: A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet. 39:359–407. 2005. View Article : Google Scholar : PubMed/NCBI
104	Yang JL, Weissman L, Bohr VA and Mattson MP: Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair (Amst). 7:1110–1120. 2008. View Article : Google Scholar
105	Levy RJ and Deutschman CS: Deficient mitochondrial biogenesis in critical illness: Cause, effect, or epiphenomenon? Crit Care. 11:1582007. View Article : Google Scholar : PubMed/NCBI
106	Elstner M, Müller SK, Leidolt L, Laub C, Krieg L, Schlaudraff F, Liss B, Morris C, Turnbull DM, Masliah E, et al: Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol Brain. 4:432011. View Article : Google Scholar : PubMed/NCBI
107	Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW and Khrapko K: Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet. 38:518–520. 2006. View Article : Google Scholar : PubMed/NCBI
108	Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, et al: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 38:515–517. 2006. View Article : Google Scholar : PubMed/NCBI
109	Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, et al: Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA. 104:1325–1330. 2007. View Article : Google Scholar : PubMed/NCBI
110	Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, et al: Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 119:866–872. 2011. View Article : Google Scholar : PubMed/NCBI
111	Halliwell B: Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging. 18:685–716. 2001. View Article : Google Scholar : PubMed/NCBI
112	Reeve AK, Krishnan KJ and Turnbull D: Mitochondrial DNA mutations in disease, aging, and neurodegeneration. Ann NY Acad Sci. 1147:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
113	Ropp PA and Copeland WC: Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. Genomics. 36:449–458. 1996. View Article : Google Scholar : PubMed/NCBI
114	Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, Oldfors A, Rautakorpi I, Peltonen L, Majamaa K, et al: Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: Clinical and molecular genetic study. Lancet. 364:875–882. 2004. View Article : Google Scholar : PubMed/NCBI
115	Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, Milone M, Cohen BH, Wical B, Ganesh J, et al: Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat. 29:E150–E172. 2008. View Article : Google Scholar : PubMed/NCBI
116	Gui YX, Xu ZP, Lv W, Zhao JJ and Hu XY: Evidence for polymerase gamma, POLG1 variation in reduced mitochondrial DNA copy number in Parkinson's disease. Parkinsonism Relat Disord. 21:282–286. 2015. View Article : Google Scholar : PubMed/NCBI
117	Hudson G and Chinnery PF: Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet. 15:R244–R252. 2006. View Article : Google Scholar : PubMed/NCBI
118	Sanders LH, McCoy J, Hu X, Mastroberardino PG, Dickinson BC, Chang CJ, Chu CT, Van Houten B and Greenamyre JT: Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol Dis. 70:214–223. 2014. View Article : Google Scholar : PubMed/NCBI
119	Wilson DM III and Barsky D: The major human abasic endonuclease: Formation, consequences and repair of abasic lesions in DNA. Mutat Res. 485:283–307. 2001. View Article : Google Scholar : PubMed/NCBI
120	Benard G and Karbowski M: Mitochondrial fusion and division: Regulation and role in cell viability. Semin Cell Dev Biol. 20:365–374. 2009. View Article : Google Scholar : PubMed/NCBI
121	Soubannier V and McBride HM: Positioning mitochondrial plasticity within cellular signaling cascades. Biochim Biophys Acta. 1793:154–170. 2009. View Article : Google Scholar
122	Schrader M: Shared components of mitochondrial and peroxisomal division. Biochim Biophys Acta. 1763:531–541. 2006. View Article : Google Scholar : PubMed/NCBI
123	Ishihara N, Jofuku A, Eura Y and Mihara K: Regulation of mitochondrial morphology by membrane potential, and DRP1-dependent division and FZO1-dependent fusion reaction in mammalian cells. Biochem Biophys Res Commun. 301:891–898. 2003. View Article : Google Scholar : PubMed/NCBI
124	Cereghetti GM, Stangherlin A, Martins de Brito O, Chang CR, Blackstone C, Bernardi P and Scorrano L: Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci USA. 105:15803–15808. 2008. View Article : Google Scholar : PubMed/NCBI
125	Han XJ, Lu YF, Li SA, Kaitsuka T, Sato Y, Tomizawa K, Nairn AC, Takei K, Matsui H and Matsushita M: CaM kinase I alpha-induced phosphorylation of Drp1 regulates mitochondrial morphology. J Cell Biol. 182:573–585. 2008. View Article : Google Scholar : PubMed/NCBI
126	Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U and Mao P: Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Brain Res Rev. 67:103–118. 2011. View Article : Google Scholar
127	James DI, Parone PA, Mattenberger Y and Martinou JC: hFis1, a novel component of the mammalian mitochondrial fission machinery. J Biol Chem. 278:36373–36379. 2003. View Article : Google Scholar : PubMed/NCBI
128	Gomes LC and Scorrano L: High levels of Fis1, a pro-fission mitochondrial protein, trigger autophagy. Biochim Biophys Acta. 1777:860–866. 2008. View Article : Google Scholar : PubMed/NCBI
129	Santos D and Cardoso SM: Mitochondrial dynamics and neuronal fate in Parkinson's disease. Mitochondrion. 12:428–437. 2012. View Article : Google Scholar : PubMed/NCBI
130	Reddy PH: Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol. 218:286–292. 2009. View Article : Google Scholar : PubMed/NCBI
131	Reddy PH: Mitochondrial dysfunction in aging and Alzheimer's disease: Strategies to protect neurons. Antioxid Redox Signal. 9:1647–1658. 2007. View Article : Google Scholar : PubMed/NCBI
132	Chen H, Chomyn A and Chan DC: Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem. 280:26185–26192. 2005. View Article : Google Scholar : PubMed/NCBI
133	Ishihara N, Eura Y and Mihara K: Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. J Cell Sci. 117:6535–6546. 2004. View Article : Google Scholar : PubMed/NCBI
134	Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, et al: Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 36:449–451. 2004. View Article : Google Scholar : PubMed/NCBI
135	Armstrong JS: Mitochondria-directed therapeutics. Antioxid Redox Signal. 10:575–578. 2008. View Article : Google Scholar
136	Chan DC: Mitochondria: Dynamic organelles in disease, aging, and development. Cell. 125:1241–1252. 2006. View Article : Google Scholar : PubMed/NCBI
137	McBride HM, Neuspiel M and Wasiak S: Mitochondria: More than just a powerhouse. Curr Biol. 16:R551–R560. 2006. View Article : Google Scholar : PubMed/NCBI
138	Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Gräber S, Kovacs I, Lee WD, Waggoner J, Cui J, et al: Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 25:3900–3911. 2006. View Article : Google Scholar : PubMed/NCBI
139	Head B, Griparic L, Amiri M, Gandre-Babbe S and van der Bliek AM: Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. J Cell Biol. 187:959–966. 2009. View Article : Google Scholar : PubMed/NCBI
140	Abou-Sleiman PM, Muqit MM and Wood NW: Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 7:207–219. 2006. View Article : Google Scholar : PubMed/NCBI
141	Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H and Lu B: Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA. 103:10793–10798. 2006. View Article : Google Scholar : PubMed/NCBI
142	Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM and Chung J: Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 441:1157–1161. 2006. View Article : Google Scholar : PubMed/NCBI
143	Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP and Youle RJ: Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol. 191:933–942. 2010. View Article : Google Scholar : PubMed/NCBI
144	Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR and Youle RJ: PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 8:e10002982010. View Article : Google Scholar : PubMed/NCBI
145	Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM and Chung J: PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun. 377:975–980. 2008. View Article : Google Scholar : PubMed/NCBI
146	Sha D, Chin LS and Li L: Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Hum Mol Genet. 19:352–363. 2010. View Article : Google Scholar
147	Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ and Springer W: PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 12:119–131. 2010. View Article : Google Scholar : PubMed/NCBI